Profile data is unavailable for this security.
About the company
Natco Pharma Limited is an India-based vertically integrated, research and development (R&D)-focused pharmaceutical company. The Company is engaged in the business of pharmaceuticals, which comprises research and development, manufacturing and selling of bulk drugs and finished dosage formulations. The Company deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The Company operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.
- Revenue in INR (TTM)38.28bn
- Net income in INR12.78bn
- Incorporated1981
- Employees3.98k
- LocationNatco Pharma LtdNatco House, Road No 2, Banjara HillsHYDERABAD 500034IndiaIND
- Phone+91 4 023547532
- Fax+91 4 023545298
- Websitehttp://www.natcopharma.co.in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jubilant Pharmova Ltd | 66.22bn | 378.60m | 90.24bn | 1.03k | 235.19 | -- | 15.40 | 1.36 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
Glenmark Life Sciences Ltd | 23.68bn | 5.19bn | 95.16bn | 1.82k | 18.33 | -- | 16.70 | 4.02 | 42.36 | 42.36 | 193.15 | -- | -- | -- | -- | 12,982,110.00 | -- | -- | -- | -- | 55.92 | -- | 21.93 | -- | -- | 538.47 | -- | -- | 1.79 | -- | 11.52 | -- | -- | -- |
Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 99.89bn | 777.00 | 22.94 | -- | 20.40 | 6.13 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
Granules India Ltd | 45.26bn | 3.95bn | 104.25bn | 3.65k | 26.36 | -- | 17.43 | 2.30 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
Eris Lifesciences Ltd | 18.61bn | 3.86bn | 114.72bn | 3.55k | 29.73 | -- | 21.14 | 6.16 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 119.52bn | 407.00 | -- | -- | -- | 112.04 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 133.21bn | 947.00 | 95.63 | -- | 86.10 | 11.13 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
Concord Biotech Ltd | 9.71bn | 3.05bn | 159.10bn | -- | 52.88 | -- | 44.36 | 16.39 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
Piramal Pharma Ltd | 77.82bn | -333.40m | 169.88bn | 6.30k | -- | -- | 24.43 | 2.18 | -0.3002 | -0.3002 | 63.15 | -- | -- | -- | -- | 12,362,800.00 | -- | -- | -- | -- | 64.29 | -- | -0.4284 | -- | -- | 6.36 | -- | -- | 7.97 | -- | -149.60 | -- | -- | -- |
Natco Pharma Ltd. | 38.28bn | 12.78bn | 170.52bn | 3.98k | 13.44 | -- | 11.76 | 4.45 | 70.84 | 70.84 | 212.24 | -- | -- | -- | -- | 9,621,513.00 | -- | 10.34 | -- | 12.04 | 78.26 | 75.11 | 33.38 | 22.66 | -- | 90.50 | -- | 21.34 | 39.20 | 4.22 | 320.76 | 0.5428 | -19.11 | -8.34 |
Suven Pharmaceuticals Ltd | 11.68bn | 3.71bn | 172.37bn | 1.17k | 46.45 | -- | 41.04 | 14.76 | 14.58 | 14.58 | 45.91 | -- | -- | -- | -- | 10,023,860.00 | -- | -- | -- | -- | 58.68 | -- | 31.76 | -- | -- | 86.09 | -- | -- | 1.52 | -- | -9.37 | -- | -- | -- |
Sanofi India Ltd | 28.51bn | 6.03bn | 186.87bn | 3.53k | 31.00 | 18.41 | 29.08 | 6.55 | 261.78 | 261.78 | 1,237.96 | 440.80 | 1.51 | 2.24 | 21.86 | -- | 31.84 | 22.42 | 50.35 | 30.21 | 57.88 | 55.69 | 21.15 | 21.03 | 0.897 | 449.47 | 0.0184 | 58.18 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
Piramal Enterprises Ltd | 79.98bn | -20.16bn | 189.86bn | 12.22k | -- | -- | -- | 2.37 | -90.77 | -90.77 | 339.88 | -- | -- | -- | -- | 6,545,270.00 | -- | 3.41 | -- | 4.51 | 47.29 | 88.04 | -25.21 | 26.30 | -- | 0.2287 | -- | 22.74 | 6.82 | -4.74 | 528.31 | 14.25 | -24.79 | 4.90 |
Pfizer Ltd | 22.19bn | 5.02bn | 191.91bn | 1.70k | 38.22 | -- | 33.26 | 8.65 | 109.76 | 109.76 | 485.08 | -- | -- | -- | -- | 13,038,660.00 | -- | 13.81 | -- | 17.63 | 63.08 | 61.21 | 22.63 | 23.22 | -- | 50.30 | -- | 84.31 | -7.13 | 4.13 | 1.86 | 11.62 | -8.75 | 11.84 |
Alembic Pharmaceuticals Ltd | 61.18bn | 5.90bn | 193.58bn | 14.59k | 32.80 | -- | 22.08 | 3.16 | 30.02 | 30.02 | 311.22 | -- | -- | -- | -- | 4,192,490.00 | -- | 11.45 | -- | 15.39 | 71.10 | 66.43 | 9.80 | 13.65 | -- | 10.21 | -- | 25.26 | 6.54 | 12.54 | -34.35 | -3.69 | -11.61 | 14.87 |
Laurus Labs Ltd | 49.82bn | 1.88bn | 211.46bn | 5.75k | 112.88 | -- | 37.13 | 4.24 | 3.48 | 3.48 | 92.17 | -- | -- | -- | -- | 8,659,934.00 | -- | 11.78 | -- | 19.75 | 51.73 | 48.41 | 4.02 | 14.16 | -- | 2.50 | -- | 12.37 | 22.39 | 23.90 | -4.52 | 36.36 | 20.42 | 31.95 |
Holder | Shares | % Held |
---|---|---|
Life Insurance Corporation of India (Investment Portfolio)as of 30 Jun 2023 | 7.37m | 4.12% |
Mirae Asset Investment Managers (India) Pvt Ltd.as of 29 Feb 2024 | 4.76m | 2.66% |
The Vanguard Group, Inc.as of 07 Mar 2024 | 3.46m | 1.93% |
Tata Asset Management Ltd.as of 29 Feb 2024 | 1.63m | 0.91% |
BlackRock Fund Advisorsas of 07 Mar 2024 | 1.45m | 0.81% |
Kotak Mahindra Life Insurance Co., Ltd.as of 29 Feb 2024 | 1.39m | 0.78% |
Dimensional Fund Advisors LPas of 07 Mar 2024 | 1.31m | 0.73% |
Jupiter Asset Management Ltd.as of 30 Nov 2023 | 943.17k | 0.53% |
Norges Bank Investment Managementas of 31 Dec 2023 | 768.12k | 0.43% |
Mahindra Manulife Investment Management Pvt Ltd.as of 29 Feb 2024 | 570.49k | 0.32% |